Sort by: after hours % change | delayed % change | gain open | gain high | gain close | publishing date
tags : Trial symbols : Abbv save search
Dragonfly has Received Milestone Payment Following Dosing of First Patient in AbbVie Phase 1 Clinical Trial Evaluating DF4101/ABBV-303
Published: 2024-03-05 (Crawled : 12:00) - prnewswire.com
ABBV | News | $164.66 0.25% -0.15% 4.5M
|
Health Technology
|
| O: -0.24%
H: 0.0%
C: 0.0%
df4101 dragonfly first abbvie payment trial milestone
Lutikizumab Showed Positive Results in a Phase 2 Trial of Adults with Moderate to Severe Hidradenitis Suppurativa as Program Advances to Phase 3
Published: 2024-01-08 (Crawled : 13:00) - prnewswire.com
ABBV | News | $164.66 0.25% -0.15% 4.5M
|
Health Technology
|
| O: 0.52%
H: 0.0%
C: 0.0%
positive program trial results
AbbVie Announces Positive Topline Results from Phase 2 LUMINOSITY Trial Evaluating Telisotuzumab-Vedotin (Teliso-V) for Patients with Previously Treated Non-Small Cell Lung Cancer (NSCLC)
Published: 2023-11-29 (Crawled : 14:30) - biospace.com/
ABBV | News | $164.66 0.25% -0.15% 4.5M
|
Health Technology
|
| O: -0.73%
H: 0.78%
C: 0.35%
lung abbvie positive cancer cell topline trial results
Trishula Therapeutics Initiates Phase 2 Trial of TTX-030, an Anti-CD39 Antibody, in First Line Metastatic Pancreatic Cancer Patients
Published: 2023-11-09 (Crawled : 14:00) - biospace.com/
ABBV | News | $164.66 0.25% -0.15% 4.5M
|
Health Technology
|
| O: -1.81%
H: 0.43%
C: -2.1%
ttx-030 cancer pancreatic trial therapeutics phase 2
Lupus Therapeutics Partners with AbbVie on Clinical Trial Recruitment Efforts in SLE Through LuCIN Lupus Clinical Trial Network
Published: 2023-10-24 (Crawled : 13:30) - biospace.com/
ABBV | News | $164.66 0.25% -0.15% 4.5M
|
Health Technology
|
| O: 0.3%
H: 0.0%
C: 0.0%
abbvie lupus network trial therapeutics
AbbVie Announces Upadacitinib (RINVOQ®) Met the Primary Endpoint in Phase 2 Clinical Trial of Vitiligo as Program Advances to Phase 3
Published: 2023-10-12 (Crawled : 11:00) - biospace.com/
ABBV | News | $164.66 0.25% -0.15% 4.5M
|
Health Technology
|
| O: -0.65%
H: 0.0%
C: 0.0%
rinvoq abbvie program trial
Alector Announces Completion of Enrollment in the INVOKE-2 Phase 2 Clinical Trial of AL002, a TREM2 Monoclonal Antibody, in Individuals With Early Alzheimer’s Disease
Published: 2023-09-07 (Crawled : 11:00) - globenewswire.com
ABBV | News | $164.66 0.25% -0.15% 4.5M
|
Health Technology
|
| O: 0.13%
H: 1.95%
C: 1.89%
ALEC | $5.1 0.59% 0.59% 410K
|
Health Technology
|
| O: -1.24%
H: 10.79%
C: 8.09%
al002 disease alzheimer’s trial
AbbVie Advances Immunology Pipeline with First Patient Dosed in Global Phase 3 Trial of Upadacitinib (RINVOQ®) in Hidradenitis Suppurativa
Published: 2023-07-24 (Crawled : 12:00) - prnewswire.com
UBS J | $28.12 0.04% 0.0% 2.3M
|
Finance
|
| O: 0.85%
H: 0.33%
C: -0.23%
ABBV | News | $164.66 0.25% -0.15% 4.5M
|
Health Technology
|
| O: 0.48%
H: 0.0%
C: 0.0%
rinvoq abbvie pipeline global immunology trial
AbbVie and Genmab Announce Positive Topline Results from Phase 1/2 EPCORE™ NHL-1 Trial Evaluating Epcoritamab (DuoBody®-CD3xCD20) in Patients with Relapsed/Refractory Follicular Lymphoma (FL)
Published: 2023-06-27 (Crawled : 23:00) - prnewswire.com
ABBV | News | $164.66 0.25% -0.15% 4.5M
|
Health Technology
|
| O: 0.0%
H: 0.43%
C: -0.07%
GMAB | $28.32 -0.74% -0.74% 240K
|
Health Technology
|
| O: -1.28%
H: 0.97%
C: 0.86%
cd20 duobody abbvie positive topline trial results
Genmab and AbbVie Announce Positive Topline Results from Phase 1/2 EPCORE™ NHL-1 Trial Evaluating Epcoritamab (DuoBody® CD3xCD20) in Patients with Relapsed/Refractory Follicular Lymphoma (FL)
Published: 2023-06-27 (Crawled : 23:00) - globenewswire.com
GNMSF | $281.02 3.83% 210
|
Health Technology
|
| O: 0.91%
H: 0.0%
C: -1.43%
ABBV | News | $164.66 0.25% -0.15% 4.5M
|
Health Technology
|
| O: 0.0%
H: 0.43%
C: -0.07%
GMAB | $28.32 -0.74% -0.74% 240K
|
Health Technology
|
| O: -1.28%
H: 0.97%
C: 0.86%
cd20 duobody abbvie positive topline trial results
Coherus Announces Positive Final Overall Survival Results of JUPITER-02 Phase 3 Trial Evaluating Toripalimab in Nasopharyngeal Carcinoma
Published: 2023-06-05 (Crawled : 22:00) - globenewswire.com
ABBV | News | $164.66 0.25% -0.15% 4.5M
|
Health Technology
|
| O: 0.45%
H: 0.05%
C: -1.48%
CHRS | $1.99 -7.44% -8.04% 1.9M
|
Health Technology
|
| O: 0.4%
H: 9.6%
C: 5.4%
piter-02 positive trial results
DelveInsight Evaluates a Robust Dry Eye Disease Clinical Trial Pipeline as 60+ Influential Pharma Players to Set Foot in the Domain
Published: 2023-05-23 (Crawled : 15:00) - prnewswire.com
NVSEF | $93.6375 6.88% 82K
|
Health Technology
|
| O: -1.22%
H: 0.0%
C: -0.62%
NVS | $92.57 -0.55% 0.0% 910K
|
Health Technology
|
| O: 0.74%
H: 0.0%
C: -1.22%
GKOS M | $95.13 -1.82% 0.0% 380K
|
Health Technology
|
| O: -0.71%
H: 2.06%
C: -1.05%
BHC | $8.6 -0.69% 0.0% 2.1M
|
Health Technology
|
| O: -2.27%
H: 4.24%
C: -2.21%
ALC | $78.47 -0.67% -0.01% 760K
|
Health Technology
|
| O: -0.51%
H: 0.02%
C: -3.25%
ABBV | News | $164.66 0.25% -0.15% 4.5M
|
Health Technology
|
| O: -0.31%
H: 0.26%
C: -1.34%
SNY | News | $45.395 -1.55% -1.58% 4.4M
|
Health Technology
|
| O: -0.01%
H: 0.0%
C: 0.0%
OCUL | News | $5.86 -22.69% -29.35% 6.1M
|
Health Technology
|
| O: 4.45%
H: 7.65%
C: 2.21%
GRFS | News | $6.53 -0.76% -0.77% 760K
|
Health Technology
|
| O: 0.78%
H: 0.0%
C: -3.74%
ALDX | News | $3.99 0.5% 0.5% 430K
|
Health Technology
|
| O: 0.0%
H: 2.36%
C: 0.61%
pharma disease pipeline set eye trial
AbbVie Announces Late-Breaking Results from Phase 3 Trial Evaluating Atogepant (QULIPTA®) for the Preventive Treatment of Episodic Migraine Among Patients with Prior Treatment Failure at the 2023 AAN Annual Meeting
Published: 2023-04-21 (Crawled : 05:00) - prnewswire.com
ABBV | News | $164.66 0.25% -0.15% 4.5M
|
Health Technology
|
| O: 0.53%
H: 0.37%
C: -0.11%
qulipta abbvie treatment meeting trial migraine results
AbbVie Announces Late-Breaking Results from Phase 2 Exploratory NOVA Trial of Novel Investigational Neurotoxin AGN-151607 for the Prevention of Postoperative Atrial Fibrillation in Cardiac Surgery Patients
Published: 2022-11-07 (Crawled : 18:00) - prnewswire.com
ABBV | News | $164.66 0.25% -0.15% 4.5M
|
Health Technology
|
| O: 0.0%
H: 2.42%
C: 1.94%
agn-1516 cardiac trial
Despite $2B AML Deal, AbbVie Stops Early Cancer Combo Trial With I-Mab
Published: 2022-08-17 (Crawled : 14:00) - biospace.com/
ABBV | News | $164.66 0.25% -0.15% 4.5M
|
Health Technology
|
| O: -0.79%
H: 0.95%
C: 0.01%
IMAB | $1.795 -0.83% -0.84% 140K
|
Health Technology
|
| O: -4.39%
H: 0.52%
C: -10.37%
aml trial cancer
AbbVie Announces Late-Breaking Results from Phase 2 Trial of Investigational Epcoritamab (DuoBody®-CD3xCD20) in Patients with Relapsed/Refractory Large B-cell Lymphoma (LBCL) at the European Hematology Association (EHA) Annual Congress
Published: 2022-06-11 (Crawled : 16:20) - prnewswire.com
ABBV | News | $164.66 0.25% -0.15% 4.5M
|
Health Technology
| Email alert
Add to watchlist
cd20 duobody trial results
AbbVie and Genmab Announce Topline Results for Epcoritamab (DuoBody®-CD3xCD20) from Phase 1/2 Trial in Patients with Relapsed/Refractory Large B-cell Lymphoma (LBCL)
Published: 2022-04-13 (Crawled : 23:00) - prnewswire.com
GNMSF | $281.02 3.83% 210
|
Health Technology
|
| O: -0.14%
H: 3.21%
C: 1.5%
ABBV | News | $164.66 0.25% -0.15% 4.5M
|
Health Technology
|
| O: -0.69%
H: 3.81%
C: 2.83%
GMAB | $28.32 -0.74% -0.74% 240K
|
Health Technology
|
| O: -0.86%
H: 2.28%
C: -0.08%
cd20 duobody topline trial phase 1
Genmab and AbbVie Announce Topline Results for Epcoritamab (DuoBody®-CD3xCD20) From Phase 1/2 Trial in Patients with Relapsed/Refractory Large B-cell Lymphoma (LBCL)
Published: 2022-04-13 (Crawled : 22:00) - globenewswire.com
GNMSF | $281.02 3.83% 210
|
Health Technology
|
| O: -0.14%
H: 3.21%
C: 1.5%
ABBV | News | $164.66 0.25% -0.15% 4.5M
|
Health Technology
|
| O: -0.69%
H: 3.81%
C: 2.83%
GMAB | $28.32 -0.74% -0.74% 240K
|
Health Technology
|
| O: -0.86%
H: 2.28%
C: -0.08%
cd20 duobody topline trial phase 1
Junshi Biosciences and Coherus Announce Positive Interim Overall Survival Results of CHOICE-01, a Phase 3 Clinical Trial Evaluating Toripalimab in Combination with Chemotherapy as First-Line Treatment for Non-Small Cell Lung Cancer
Published: 2021-12-13 (Crawled : 21:00) - globenewswire.com
ABBV | News | $164.66 0.25% -0.15% 4.5M
|
Health Technology
|
| O: 1.07%
H: 0.0%
C: 0.0%
CHRS | $1.99 -7.44% -8.04% 1.9M
|
Health Technology
|
| O: -0.83%
H: 0.0%
C: 0.0%
hoice-01 treatment trial lung cancer positive therapy bioscience results cancer phase 3
AbbVie Presents Integrated Efficacy and Safety Data From Two Phase 3 Trials on Risankizumab (SKYRIZI®) in Psoriatic Arthritis at ACR Convergence 2021
Published: 2021-11-05 (Crawled : 16:00) - biospace.com/
ABBV | News | $164.66 0.25% -0.15% 4.5M
|
Health Technology
|
| O: -0.28%
H: 0.51%
C: 0.39%
trials phase 3 risankizumab trial
Gainers vs Losers
| 64% | 36% |
Top 10 Gainers
AGBA | News | $1.02 155.0% 57.94% 120M
|
Finance
ZCMD | $2.86 108.76% 52.1% 2.3M
|
Commercial Services
INVO | $1.555 104.6% 51.13% 5M
|
Health Technology
ISPC | $0.437 105.16% 49.53% 37M
|
Professional, Scientific, and T...
WLGS | News | $0.92 84.0% 45.65% 1.6M
|
OST | $0.499 21.38% 45.26% 1.9M
|
XPON | News | $3.1 60.62% 37.74% 17M
|
TIRX | $0.7 44.39% 30.74% 58M
|
BNTC | News | $6.92 44.17% 30.64% 3.5M
|
Health Technology
GGE | $0.035 19.86% 29.3% 64M
|
Your saved searches
Save your searches and get alerts when important news are released.